Preventing infections in central lines for people on IV nutrition
Treatments studied
Part of Infections clinical trials.
This trial tests a new catheter lock solution (DefenCath) to prevent infections in people who need long-term IV nutrition through a central line. It compares the study drug to a standard heparin lock, and you'll be randomly assigned to one group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a permanent central line (like a tunneled catheter or PICC) that's been in for at least 7 days
- You need IV nutrition (TPN) for more than 6 months, at least 3 days a week (with 2 of those being full nutrition)
- You are 18 or older and live in the US or Turkey
- You have not taken any antibiotics (by mouth or IV) in the last 14 days
- You are willing to have your line locked with the study drug (or a placebo) every 7 days, and you can be trained to do it or have a caregiver who can
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses machine learning to predict infections that can happen with central lines (special IVs placed in large veins) and aims to reduce how often they occur. It focuses on hospitals with the highest infection rates, so you might be eligible if you receive care at one of these hospitals.
This trial tests whether using a special skin/line “tissue glue” around IV line sites can lower the risk of bloodstream infections in critically ill children with heart disease. It may help reduce infection rates and line-related complications in children considered high risk.
This study tests a special locking solution placed in central venous catheters (thin tubes in babies' veins) to prevent infections. Researchers want to see if this approach keeps newborns safer during hospital care.
This study aims to reduce infections that can happen when you have a central line, a special tube placed in a large vein to give medicines or fluids. Participating may help improve safety for patients like you.
This trial studies how to make central lines safer by testing different ways to secure them and what caps to use. It is for people who need a central line, including those with cancer, and focuses on preventing infections.
This trial studies whether a medicine lock called taurolidine is safer or works better than a standard saline (salt water) lock for pediatric cancer patients with central venous lines. It’s meant to help prevent central-line infections.
Hear when a new Central Line Associated Blood Stream Infections (CLABSI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.